Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sandoz Group Ltd ( (CH:SDZ) ) has issued an announcement.
Sandoz has signed a major license, development and commercialization partnership with Samsung Bioepis for up to five biosimilar medicines, starting with a vedolizumab biosimilar referencing Takeda’s Entyvio for inflammatory bowel diseases. Under the deal, Samsung Bioepis will handle development, key regulatory filings and manufacturing, while Sandoz gains exclusive commercialization rights worldwide except in China, Hong Kong, Taiwan, Macau and South Korea.
The agreement could expand Sandoz’s biosimilar pipeline to as many as 32 assets and deepens an existing alliance that already covers ustekinumab and eculizumab biosimilars in various regions. By reinforcing its presence in a global biosimilar market with an estimated USD 320 billion loss-of-exclusivity opportunity over the next decade, Sandoz is positioning itself to capture a larger share of future volume growth and cost-saving opportunities for healthcare systems and patients.
The most recent analyst rating on (CH:SDZ) stock is a Hold with a CHF75.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz Group AG, headquartered in Basel, Switzerland, is a global leader in affordable medicines with a portfolio of around 1,300 drugs spanning conditions from the common cold to cancer. The company, which generated USD 11.1 billion in net sales in 2025, is a long-standing pioneer in biosimilars and antibiotics, serving over one billion patients in nearly 100 countries.
Average Trading Volume: 807,428
Technical Sentiment Signal: Buy
Current Market Cap: CHF27.68B
Find detailed analytics on SDZ stock on TipRanks’ Stock Analysis page.